List of Tables
Table 1. Major Company of NMDA
Table 2. Major Company of SSRIs
Table 3. Major Company of Dopamine Inhibitors
Table 4. Global Neurodegenerative Drugs Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Neurodegenerative Drugs Sales by Type (2018-2023) & (MT)
Table 6. Global Neurodegenerative Drugs Sales Market Share in Volume by Type (2018-2023)
Table 7. Global Neurodegenerative Drugs Sales by Type (2018-2023) & (US& Million)
Table 8. Global Neurodegenerative Drugs Market Share in Value by Type (2018-2023)
Table 9. Global Neurodegenerative Drugs Price by Type (2018-2023) & (US$/MT)
Table 10. Global Neurodegenerative Drugs Sales by Type (2024-2029) & (MT)
Table 11. Global Neurodegenerative Drugs Sales Market Share in Volume by Type (2024-2029)
Table 12. Global Neurodegenerative Drugs Sales by Type (2024-2029) & (US$ Million)
Table 13. Global Neurodegenerative Drugs Sales Market Share in Value by Type (2024-2029)
Table 14. Global Neurodegenerative Drugs Price by Type (2024-2029) & (US$/MT)
Table 15. North America Neurodegenerative Drugs Sales by Type (2018-2023) & (MT)
Table 16. North America Neurodegenerative Drugs Sales by Type (2018-2023) & (US$ Million)
Table 17. Europe Neurodegenerative Drugs Sales (MT) by Type (2018-2023)
Table 18. Europe Neurodegenerative Drugs Sales by Type (2018-2023) & (US$ Million)
Table 19. Asia-Pacific Neurodegenerative Drugs Sales (MT) by Type (2018-2023)
Table 20. Asia-Pacific Neurodegenerative Drugs Sales by Type (2018-2023) & (US$ Million)
Table 21. Latin America Neurodegenerative Drugs Sales (MT) by Type (2018-2023)
Table 22. Latin America Neurodegenerative Drugs Sales by Type (2018-2023) & (US$ Million)
Table 23. Middle East and Africa Neurodegenerative Drugs Sales (MT) by Type (2018-2023)
Table 24. Middle East and Africa Neurodegenerative Drugs Sales by Type (2018-2023) & (US$ Million)
Table 25. Global Neurodegenerative Drugs Sales by Company (2018-2023) & (MT)
Table 26. Global Neurodegenerative Drugs Sales Share by Company (2018-2023)
Table 27. Global Neurodegenerative Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 28. Global Neurodegenerative Drugs Revenue Share by Company (2018-2023)
Table 29. Global Market Neurodegenerative Drugs Price by Company (2018-2023) & (US$/MT)
Table 30. Global Neurodegenerative Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Neurodegenerative Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2022)
Table 33. Date of Key Manufacturers Enter into Neurodegenerative Drugs Market
Table 34. Key Manufacturers Neurodegenerative Drugs Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Neurodegenerative Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 37. Global Neurodegenerative Drugs Sales by Region (2018-2023) & (MT)
Table 38. Global Neurodegenerative Drugs Sales Market Share in Volume by Region (2018-2023)
Table 39. Global Neurodegenerative Drugs Sales by Region (2018-2023) & (US$ Million)
Table 40. Global Neurodegenerative Drugs Sales Market Share in Value by Region (2018-2023)
Table 41. Global Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2018-2023)
Table 42. Global Neurodegenerative Drugs Sales by Region (2024-2029) & (MT)
Table 43. Global Neurodegenerative Drugs Sales Market Share in Volume by Region (2024-2029)
Table 44. Global Neurodegenerative Drugs Sales by Region (2024-2029) & (US$ Million)
Table 45. Global Neurodegenerative Drugs Sales Market Share in Value by Region (2024-2029)
Table 46. Global Neurodegenerative Drugs Sales (MT), Revenue (US$ Million), Price (US$/MT) and Gross Margin (2024-2029)
Table 47. Global Neurodegenerative Drugs Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 48. Global Neurodegenerative Drugs Sales by Application (2018-2023) & (MT)
Table 49. Global Neurodegenerative Drugs Sales Market Share in Volume by Application (2018-2023)
Table 50. Global Neurodegenerative Drugs Sales by Application (2018-2023) & (US$ Million)
Table 51. Global Neurodegenerative Drugs Sales Market Share in Value by Application (2018-2023)
Table 52. Global Neurodegenerative Drugs Price by Application (2018-2023) & (US$/MT)
Table 53. Global Neurodegenerative Drugs Sales by Application (2024-2029) & (MT)
Table 54. Global Neurodegenerative Drugs Sales Market Share in Volume by Application (2024-2029)
Table 55. Global Neurodegenerative Drugs Sales by Application (2024-2029) & (US$ Million)
Table 56. Global Neurodegenerative Drugs Sales Market Share in Value by Application (2024-2029)
Table 57. Global Neurodegenerative Drugs Price by Application (2024-2029) & (US$/MT)
Table 58. North America Neurodegenerative Drugs Sales by Application (2018-2023) (MT)
Table 59. North America Neurodegenerative Drugs Sales by Application (2018-2023) & (US$ Million)
Table 60. Europe Neurodegenerative Drugs Sales by Application (2018-2023) (MT)
Table 61. Europe Neurodegenerative Drugs Sales by Application (2018-2023) & (US$ Million)
Table 62. Asia-Pacific Neurodegenerative Drugs Sales by Application (2018-2023) (MT)
Table 63. Asia-Pacific Neurodegenerative Drugs Sales by Application (2018-2023) & (US$ Million)
Table 64. Latin America Neurodegenerative Drugs Sales by Application (2018-2023) (MT)
Table 65. Latin America Neurodegenerative Drugs Sales by Application (2018-2023) & (US$ Million)
Table 66. Middle East and Africa Neurodegenerative Drugs Sales by Application (2018-2023) (MT)
Table 67. Middle East and Africa Neurodegenerative Drugs Sales by Application (2018-2023) & (US$ Million)
Table 68. North America Neurodegenerative Drugs Sales by Country (2018-2023) & (MT)
Table 69. North America Neurodegenerative Drugs Sales Market Share in Volume by Country (2018-2023)
Table 70. North America Neurodegenerative Drugs Sales by Country (2018-2023) & (US$ Million)
Table 71. North America Neurodegenerative Drugs Sales Market Share in Value by Country (2018-2023)
Table 72. North America Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 73. North America Neurodegenerative Drugs Sales Market Share in Volume by Country (2024-2029)
Table 74. North America Neurodegenerative Drugs Sales by Country (2024-2029) & (US$ Million)
Table 75. North America Neurodegenerative Drugs Sales Market Share in Value by Country (2024-2029)
Table 76. Europe Neurodegenerative Drugs Sales by Country (2018-2023) & (MT)
Table 77. Europe Neurodegenerative Drugs Sales Market Share in Volume by Country (2018-2023)
Table 78. Europe Neurodegenerative Drugs Sales by Country (2018-2023) & (US$ Million)
Table 79. Europe Neurodegenerative Drugs Sales Market Share in Value by Country (2018-2023)
Table 80. Europe Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 81. Europe Neurodegenerative Drugs Sales Market Share in Volume by Country (2024-2029)
Table 82. Europe Neurodegenerative Drugs Sales by Country (2024-2029) & (US$ Million)
Table 83. Europe Neurodegenerative Drugs Sales Market Share in Value by Country (2024-2029)
Table 84. Asia-Pacific Neurodegenerative Drugs Sales by Region (2018-2023) & (MT)
Table 85. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Region (2018-2023)
Table 86. Asia-Pacific Neurodegenerative Drugs Sales by Region (2018-2023) & (US$ Million)
Table 87. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Region (2018-2023)
Table 88. Asia-Pacific Neurodegenerative Drugs Sales by Region (2024-2029) & (MT)
Table 89. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Region (2024-2029)
Table 90. Asia-Pacific Neurodegenerative Drugs Sales by Region (2024-2029) & (US$ Million)
Table 91. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Region (2024-2029)
Table 92. Latin America Neurodegenerative Drugs Sales by Country (2018-2023) & (MT)
Table 93. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Country (2018-2023)
Table 94. Latin America Neurodegenerative Drugs Sales by Country (2018-2023) & (US$ Million)
Table 95. Latin America Neurodegenerative Drugs Sales Market Share in Value by Country (2018-2023)
Table 96. Latin America Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 97. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Country (2024-2029)
Table 98. Latin America Neurodegenerative Drugs Sales by Country (2024-2029) & (US$ Million)
Table 99. Latin America Neurodegenerative Drugs Sales Market Share in Value by Country (2024-2029)
Table 100. Middle East and Africa Neurodegenerative Drugs Sales by Country (2018-2023) & (MT)
Table 101. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Volume by Country (2018-2023)
Table 102. Middle East and Africa Neurodegenerative Drugs Sales by Country (2018-2023) & (US$ Million)
Table 103. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Country (2018-2023)
Table 104. Middle East and Africa Neurodegenerative Drugs Sales by Country (2024-2029) & (MT)
Table 105. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Volume by Country (2024-2029)
Table 106. Middle East and Africa Neurodegenerative Drugs Sales by Country (2024-2029) & (US$ Million)
Table 107. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Country (2024-2029)
Table 108. Novartis Company Information
Table 109. Novartis Introduction and Business Overview
Table 110. Novartis Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 111. Novartis Neurodegenerative Drugs Product
Table 112. Novartis Recent Development
Table 113. Pfizer Company Information
Table 114. Pfizer Introduction and Business Overview
Table 115. Pfizer Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 116. Pfizer Neurodegenerative Drugs Product
Table 117. Pfizer Recent Development
Table 118. Merck Serono Company Information
Table 119. Merck Serono Introduction and Business Overview
Table 120. Merck Serono Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 121. Merck Serono Neurodegenerative Drugs Product
Table 122. Merck Serono Recent Development
Table 123. Biogen Idec Company Information
Table 124. Biogen Idec Introduction and Business Overview
Table 125. Biogen Idec Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 126. Biogen Idec Neurodegenerative Drugs Product
Table 127. Biogen Idec Recent Development
Table 128. TEVA Company Information
Table 129. TEVA Introduction and Business Overview
Table 130. TEVA Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 131. TEVA Neurodegenerative Drugs Product
Table 132. TEVA Recent Development
Table 133. UCB Company Information
Table 134. UCB Introduction and Business Overview
Table 135. UCB Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 136. UCB Neurodegenerative Drugs Product
Table 137. UCB Recent Development
Table 138. Boehringer Ingelheim Company Information
Table 139. Boehringer Ingelheim Introduction and Business Overview
Table 140. Boehringer Ingelheim Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 141. Boehringer Ingelheim Neurodegenerative Drugs Product
Table 142. Boehringer Ingelheim Recent Development
Table 143. Sanofi Company Information
Table 144. Sanofi Introduction and Business Overview
Table 145. Sanofi Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 146. Sanofi Neurodegenerative Drugs Product
Table 147. Sanofi Recent Development
Table 148. GlaxoSmithKline Company Information
Table 149. GlaxoSmithKline Introduction and Business Overview
Table 150. GlaxoSmithKline Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 151. GlaxoSmithKline Neurodegenerative Drugs Product
Table 152. GlaxoSmithKline Recent Development
Table 153. Livzon Pharmaceutical Company Information
Table 154. Livzon Pharmaceutical Introduction and Business Overview
Table 155. Livzon Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 156. Livzon Pharmaceutical Neurodegenerative Drugs Product
Table 157. Livzon Pharmaceutical Recent Development
Table 158. Haisco Pharmaceutical Company Information
Table 159. Haisco Pharmaceutical Introduction and Business Overview
Table 160. Haisco Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 161. Haisco Pharmaceutical Neurodegenerative Drugs Product
Table 162. Haisco Pharmaceutical Recent Development
Table 163. Jingxin Pharmaceutical Company Information
Table 164. Jingxin Pharmaceutical Introduction and Business Overview
Table 165. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 166. Jingxin Pharmaceutical Neurodegenerative Drugs Product
Table 167. Jingxin Pharmaceutical Recent Development
Table 168. Dongcheng Biochemicals Company Information
Table 169. Dongcheng Biochemicals Introduction and Business Overview
Table 170. Dongcheng Biochemicals Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 171. Dongcheng Biochemicals Neurodegenerative Drugs Product
Table 172. Dongcheng Biochemicals Recent Development
Table 173. Hisun Pharmaceutical Company Information
Table 174. Hisun Pharmaceutical Introduction and Business Overview
Table 175. Hisun Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 176. Hisun Pharmaceutical Neurodegenerative Drugs Product
Table 177. Hisun Pharmaceutical Recent Development
Table 178. Luye Pharma Company Information
Table 179. Luye Pharma Introduction and Business Overview
Table 180. Luye Pharma Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 181. Luye Pharma Neurodegenerative Drugs Product
Table 182. Luye Pharma Recent Development
Table 183. Ark Pharmaceutical Company Information
Table 184. Ark Pharmaceutical Introduction and Business Overview
Table 185. Ark Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 186. Ark Pharmaceutical Neurodegenerative Drugs Product
Table 187. Ark Pharmaceutical Recent Development
Table 188. Kanghong Pharmaceutical Company Information
Table 189. Kanghong Pharmaceutical Introduction and Business Overview
Table 190. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 191. Kanghong Pharmaceutical Neurodegenerative Drugs Product
Table 192. Kanghong Pharmaceutical Recent Development
Table 193. Huahai Pharmaceutical Company Information
Table 194. Huahai Pharmaceutical Introduction and Business Overview
Table 195. Huahai Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 196. Huahai Pharmaceutical Neurodegenerative Drugs Product
Table 197. Huahai Pharmaceutical Recent Development
Table 198. BORA PHARMACEUTICALS Company Information
Table 199. BORA PHARMACEUTICALS Introduction and Business Overview
Table 200. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (MT), Revenue (Million USD), Price (US$/MT) and Gross Margin (2018-2023)
Table 201. BORA PHARMACEUTICALS Neurodegenerative Drugs Product
Table 202. BORA PHARMACEUTICALS Recent Development
Table 203. Key Raw Materials Lists
Table 204. Raw Materials Key Suppliers Lists
Table 205. Neurodegenerative Drugs Market Trends
Table 206. Neurodegenerative Drugs Market Drivers
Table 207. Neurodegenerative Drugs Market Challenges
Table 208. Neurodegenerative Drugs Market Restraints
Table 209. Neurodegenerative Drugs Distributors List
Table 210. Neurodegenerative Drugs Downstream Customers
Table 211. Research Programs/Design for This Report
Table 212. Key Data Information from Secondary Sources
Table 213. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurodegenerative Drugs Product Picture
Figure 2. Global Neurodegenerative Drugs Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Neurodegenerative Drugs Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Neurodegenerative Drugs Sales Status and Outlook (2018-2029) & (MT)
Figure 5. Product Picture of NMDA
Figure 6. Global NMDA Sales YoY Growth (2018-2029) & (MT)
Figure 7. Product Picture of SSRIs
Figure 8. Global SSRIs Sales YoY Growth (2018-2029) & (MT)
Figure 9. Product Picture of Dopamine Inhibitors
Figure 10. Global Dopamine Inhibitors Sales YoY Growth (2018-2029) & (MT)
Figure 11. Global Neurodegenerative Drugs Sales by Type (2018-2029) & (US$ Million)
Figure 12. Global Neurodegenerative Drugs Sales Market Share by Type in 2022 & 2029
Figure 13. North America Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 14. North America Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 15. Europe Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 16. Europe Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 19. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Neurodegenerative Drugs Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Neurodegenerative Drugs Revenue in 2022
Figure 25. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 26. Product Picture of Parkinson’s Disease
Figure 27. Global Parkinson’s Disease Sales YoY Growth (2018-2029) & (MT)
Figure 28. Product Picture of Huntington Disease
Figure 29. Global Huntington Disease Sales YoY Growth (2018-2029) & (MT)
Figure 30. Product Picture of Amyotrophic Lateral Sclerosis
Figure 31. Global Amyotrophic Lateral Sclerosis Sales YoY Growth (2018-2029) & (MT)
Figure 32. Product Picture of Alzheimer’s Disease
Figure 33. Global Alzheimer’s Disease Sales YoY Growth (2018-2029) & (MT)
Figure 34. Global Neurodegenerative Drugs Sales by Application (2018-2029) & (US$ Million)
Figure 35. Global Neurodegenerative Drugs Sales Market Share by Application in 2022 & 2029
Figure 36. North America Neurodegenerative Drugs Sales Market Share in Volume by Application in 2022
Figure 37. North America Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 38. Europe Neurodegenerative Drugs Sales Market Share in Volume by Application in 2022
Figure 39. Europe Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 42. Latin America Neurodegenerative Drugs Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Neurodegenerative Drugs Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Neurodegenerative Drugs Manufacturing Cost Structure
Figure 47. Neurodegenerative Drugs Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed